Roche’s Tecentriq has been added to the new-look Cancer Drugs Fund for bladder cancer patients, making it the latest in a recent flurry of drugs to be put on the managed access fund.
Roche has withdrawn a cancer drug from Greece, saying that a series of government-imposed price discounts have made it impossible to market the drug there.
Roche has signed a deal with Warp Drive Bio to discover and develop new antibiotics, badly needed to combat the growing threat of multi-drug resistant bacteria.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
